{"id":8055,"date":"2021-09-27T16:02:01","date_gmt":"2021-09-27T21:02:01","guid":{"rendered":"https:\/\/bethematchbiotherapies.com\/?post_type=dt_portfolio&p=8055"},"modified":"2024-04-16T12:00:32","modified_gmt":"2024-04-16T17:00:32","slug":"cell-therapy-industry-turning-point-whitepaper","status":"publish","type":"dt_portfolio","link":"https:\/\/bethematchbiotherapies.com\/resources\/cell-therapy-industry-turning-point-whitepaper\/","title":{"rendered":"A Cell Therapy Industry Turning Point"},"content":{"rendered":"

[vc_row][vc_column width=”2\/3″][vc_column_text]Starting material collection can set the fate of your final cell therapy product. Quality matters.<\/strong><\/p>\n

That\u2019s why your site qualification process\u2014including your quality system audit\u2014for each site is so important. But with the rapid proliferation of cell and gene therapies, current processes are unsustainable and could cripple cell collection site capacity.<\/p>\n

That could mean delays in your therapy development. There are solutions.<\/p>\n

In our Case In Point, the authors illustrate how standardization through a quality system audit program can create immediate efficiencies and reduce the risk of delays.<\/p>\n

Authors include:<\/p>\n